<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0502244842
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VELPHORO 500 MG CHEWABLE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PA-21 FERRIC OXY-HYDROXIDE COMPONENT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        603.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Vifor SA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Vifor SA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VIFOR INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AE05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:</p><p>On prescription from a doctor.</p><p>Velphoro contains a mixture of polynuclear iron(III) oxyhydroxide, sucrose, and starch as active substances in a quantity corresponding to 500&nbsp;mg of iron.</p><p>This medicinal product belongs to a product group that is used when phosphate levels in the blood are too high (hyperphosphataemia).</p><p>Velphoro is taken by patients with chronic renal insufficiency who undergo hemodialysis or peritoneal dialysis to treat hyperphosphataemia.</p><p>After you have taken Velphoro orally, it binds phosphate from food in the digestive tract, and thus reduces the phosphate levels in the blood as well as the amount of phosphate absorbed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;Do not take Velphoro:</strong></p><ul><li>&nbsp;If you are allergic to the active substances or to any of the other ingredients listed in the section &ldquo;What Velphoro contains&rdquo;.</li><li>If you suffer from congenital or acquired iron overloads (e.g. haemochromatosis).</li></ul><p><strong>b. Take special care with Velphoro</strong></p><p><strong>Talk to your doctor or nurse before taking Velphoro</strong></p><p>Long-term experience with taking Velphoro is limited, particularly for patients undergoing peritoneal dialysis. Talk to your doctor or pharmacist before taking Velphoro if you currently suffer from any of the following conditions:</p><ul><li>inflammation of the abdominal membrane (serous membrane) that lines the inner wall of the abdominal cavity (peritonitis),</li><li>serious gastrointestinal and/or liver disorders,</li><li>major gastrointestinal surgery,</li></ul><p>as only a few patients suffering from these disorders were studied in clinical studies with this medicinal product.</p><p>Talk to your doctor before taking Velphoro if you are not sure whether any of the above conditions apply to you.</p><p>Velphoro can cause discoloured/black stool. Potential bleeding from your digestive tract (stomach and intestines) may be masked by discolouration of the stool.</p><ul><li>If you have additional symptoms such as worsening fatigue and shortness of breath, please contact your doctor immediately.</li></ul><p>Velphoro contains sucrose and starch (carbohydrates). Consult your doctor before taking this medicinal product if you know that you suffer from an intolerance to certain sugars.It may be harmful to the teeth.</p><p>Velphoro can cause temporary discolouration of the teeth and tongue.</p><p>&nbsp;</p><p><strong>Using other medicines, herbal or dietary supplements</strong></p><p>In principle, Velphoro can affect the way that some other medicinal products work, and vice versa. However, no significant interactions with commonly used medicinal products were observed in studies with humans.</p><p>The following medicines should generally be administered at least 1&nbsp;hour before or 2&nbsp;hours after Velphoro: alendronate,&nbsp; levothyroxine, atorvastatin, bisphosphonate, tetracycline, ciprofloxacin, mycophenolate, mycophenolate mofetil, anti-HIV medicines, complexing agents (medicines with the ability to bind to minerals) and vitamin&nbsp;C.</p><p>For some medicines, it may be necessary to leave a longer period of time between taking Velphoro and taking the additional medicine (e.g. doxycycline).</p><p>It is unlikely that this medicinal product will affect your ability to drive or to use tools or machinery.</p><p>Tell your doctor or pharmacist if you</p><ul><li>suffer from other disorders,</li><li>have allergies, or</li><li>are taking other medicinal products (even those you purchased over the counter).</li></ul><p>&nbsp;</p><p><strong>c. Pregnancy and Breastfeeding</strong></p><p><strong>Pregnancy</strong></p><p>Velphoro may only be taken during pregnancy following consultation with a doctor.</p><p><strong>Breastfeeding</strong></p><p>Velphoro may only be taken when breast-feeding following consultation with a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Adult:</strong></p><p>Your doctor decides on the recommended dose. The recommended initial dose of Velphoro is 1,500&nbsp;mg per day (3&nbsp;tablets). Your doctor will adjust the dose accordingly while treating your serum phosphate levels. The maximum recommended daily dose is 3,000&nbsp;mg (6&nbsp;tablets) per day. Velphoro must be taken orally with meals.</p><ul><li>You must chew the tablet and not swallow it whole.</li><li>The tablets may be crushed to make them easier to chew.</li><li>You must not drink any additional liquids that exceed the required liquid intake for your renal disorder.</li><li>The number of tablets to be taken per day should be divided among the meals of the day.</li></ul><p>If you have accidentally taken too many tablets, do not take more tablets and consult your doctor or pharmacist immediately.</p><p>If you forget to take a dose, then skip the one you missed and take the next dose at the usual time with a meal. Do not take a double dose to make up for a forgotten dose. Do not stop taking this medicinal product until you have spoken with your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The use and safety of Velphoro in children and adolescents up to 18&nbsp;years old have not been tested yet.</p><p>Do not change the prescribed dose yourself. If you feel that the medicinal effect is too high or too low, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Velphoro can cause side effects, although not everybody gets them.</p><p>The following side effects have been observed in patients taking Velphoro:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;<p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very Commun</strong></p><p>(may affect more than 1 in 10&nbsp;people)</p></td><td style="vertical-align:top"><p><strong>Common:</strong></p><p>(may affect up to 1 in 10&nbsp;people in every 100)</p></td><td style="vertical-align:top"><p><strong>Uncommon: </strong></p><p>(may affect up to 1 in 10 people in every 1000)</p></td><td style="vertical-align:top"><p><strong>Rare:</strong></p><p>(may affect up to 1 in 10000&nbsp;people)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>high or low blood calcium levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>shortness of breath</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea*, discoloured (black) stool*</p></td><td style="vertical-align:top"><p>Nausea, constipation, vomiting, indigestion disorders, abdominal pain, bloating, temporary discolouration of the teeth</p></td><td style="vertical-align:top"><p>abdominal distension (bloating), gastritis (inflammation of the mucosal abdominal lining), abdominal discomfort, difficulty swallowing, gastroesophageal reflux disease (GORD), temporary discolouration of the tongue, loss of appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>itching, rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abnormal product taste</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Diarrhoea occurred early on in the treatment and subsided over time. As frequently occurs with iron preparations, patients who use Velphoro may very often suffer from discoloured (black) stool. Potential bleeding from your digestive tract (stomach and intestines) may be masked by discolouration of the stool.</p><p>If you suffer from additional symptoms such as worsening fatigue and shortness of breath, please contact your doctor immediately.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>To report any side effect(s):<br />▪ Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p><p>▪ United Arab Emirates:<br />Pharmacovigilance and Medical Device section, Dubai, UAE,<br />PO Box 1853, Tel 80011111,<br />Drug Department, Ministry of Health and Prevention,<br />Email: pv@mohap.gov.ae</p><p><br />▪ Kuwait:<br />Drug &amp; Food Control, Ministry of Health, Kuwait<br />Tel.: 24811532 Fax:24811507<br />E-mail Adress :Adr_reporting@moh.gov.kw<br />Website: http://eservices.moh.gov.kw/SPCMS/DrugCmp.aspx</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep Velphoro out of the sight and reach of children.</p><p>- Do not store above 30&deg;C, Store in the original package.</p><p>- Do not use Velphoro after the &ldquo;EXP&rdquo; date which is stated on the bottle</p><p>- Always keep the plastic bottle tightly closed in order to protect its contents from moisture.</p><p>- Shelf life after first opening the plastic bottle: 90&nbsp;days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Iron as sucroferric oxyhydroxide (a mixture of polynuclear iron(III)<br />oxyhydroxide, sucrose and starch).</p><p><br />Each tablet contains 500 mg iron as sucroferric oxyhydroxide (a mixture of polynuclear iron(III)<br />oxyhydroxide, sucrose and starch), flavorings and excipients.</p><p><br />Excipients<br />Magnesium stearate, silica (colloidalis anhydrica), woodberry flavour, neohesperidine<br />dihydrochalcone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The chewable tablets are round, brown, biplanar tablets, debossed with PA500 on one side.
They are packed in plastic bottles containing 90 chewable tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vifor (international) Inc.</p><p>Rechenstrasse 37, 9014 St. Gallen</p><p>Switzerland</p><p><strong>Bulk manufacturing and packaging site:</strong><br />Corden Pharma Fribourg SA<br />Route de Moncor 10, 1752 Villars-sur-Gl&acirc;ne<br />Switzerland</p><p>&nbsp;</p><p>For any information about this medicinal product, please contact the local representative</p><p>of the Marketing Authorisation Holder:</p><p><strong>Name: ARAC Health Care</strong></p><p>Address City: Riyadh</p><p>Tel: +966 11 2522618</p><p>Email: Drug.Safety@arac.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d.	This leaflet was revised in May 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>بناءً على وصفة طبية من الطبيب.<br />تحتوي أقراص فيلفورو&reg; على الحديد على هيئة أوكسي هيدروكسيد سكروز الحديد الثلاثي (خليط من أوكسي هيدروكسيد الحديد متعدد<br />النوى (الثلاثي) والسكروز والنشا) والمنكهات والسواغات.<br />ينتمي المنتج الطبي هذا لمجموعة منتج تستخدم عندما تكون مستويات الفوسفات في الدم مرتفعة جدًا (فرط فوسفاتاز الدم) .<br />يتم إعطاء أقراص فيلفورو&reg; للمرضى الذين يعانون من قصور كلوي مزمن ويجرون غسيلاً كلويًا أو غسيلاً كلويًا بريتونيًا لعلاج فرط<br />فوسفاتاز الدم.<br />بعد تناول أقراص فيلفورو&reg; عن طريق الفم، تقل نسبة الفوسفات المستخلص من الطعام في الجهاز الهضمي، وبالتالي تقل مستويات<br />الفوسفات في الدم وكذلك كمية الفوسفات الممتص.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ.&nbsp; لا تتناول أقراص فيلفور و&reg; في الحالات التالية:<br />-إذا كنت تعاني من حساسية من المواد الفعالة أو لأي من المكونات الأخرى المدرجة في قسم &quot;مكونات أقراص فيلفورو.&quot;&reg;<br />-إذا كنت تعاني من ترسب الأصبغة الدموية الخلقية أو المكتسبة (مثل الصباغ الدموي).</p><p>ب.&nbsp; يجب توخي الحذر عند تناول أقراص فيلفورو&reg;في حالة :</p><p>قبل أن تتلقى فيلفورو&reg;,&nbsp;أخبر مقدم الرعاية الصحية الخاص بك بجميع الحالات الطبية التي تشكو منها، بما في ذلك:</p><p>تكون التجربة طويلة المدى مع تناول أقراص فيلفورو&reg; محدودة وخاصة بالمرضى الذين يجرون الغسيل الكلوي. الرجاء التحدث مع&nbsp; الطبيب أو الصيدلي قبل تناول أقراص فيلفورو&reg;</p><p>إذا كنت تعاني حاليًا من أي من الحالات التالية:</p><p dir="ltr"><br />,(التهاب غشاء البطن (الغشاء المصلي) الذي يبطن الجدار الداخلي لتجويف البطن(التهاب الصفاق ●<br />،اضطرابات خطيرة بالجهاز الهضمي و /أو الكبد ●<br />،إجراء عملية جراحية كبيرة بالجهاز الهضمي ●</p><p><br />لم تتم دراسة إلا عدد قليل فقط من المرضى الذين يعانون من هذه الاضطرابات في الدراسات السريرية مع المنتج الطبي .<br />يُرجى التحدث مع الطبيب قبل تناول أقراص فيلفورو&reg; إذا كنت غير متأكد من أن هذه الحالات تنطبق عليك أم لا.<br />يمكن أن تُسبب أقراص فيلفور و&reg; تغير لون البراز/برازًا أسود. قد لا يظهر وجود نزيف محتمل من الجهاز الهضمي (المعدة والأمعاء)<br />بسبب تغير لون البراز.<br />إذا كنت تعاني من أعراض إضافية، مثل تفاقم الشعور بالإعياء وضيق التنفس، يُرجى الاتصال بالطبيب في الحال.<br />تحتوي أقراص فيلفورو&reg;على سكروز ونشا (الكربوهيدرات). الرجاء استشارة الطبيب قبل تناول المنتج الطبي إذا كنت تعلم أنك تعاني<br />من عدم التحمل لبعض السكريات. قد تكون ضارة للأسنان.<br />يمكن أن تؤدي أقراص فيلفورو &reg;إلى تغير لون الأسنان واللسان.<br />مبدئيًا، يمكن لأقراص فيلفور و&reg;أن تؤثر على طريقة عمل بعض المنتجات الطبية الأخرى والعكس بالعكس. ومع ذلك، لم تتم ملاحظة<br />أي تفاعلات دوائية خطيرة مع المنتجات الطبية المستخدمة عادة في الدراسات على البشر.<br />يجب أن يتم إعطاء الأدوية التالية عمومًا قبل ساعة واحدة ( 1) أو ساعتين ( 2) من تناول أقراص فيلفورو&reg;على الأقل: الأليندرونيك،<br />وليفوثيروكسين، وأوتروفستاتين، والبايفوسفونيت، والتتراسيكلين، والسيبروفلوكساسين، وميكوفينولات، وميكوفينولات موفيتل، وأدوية&nbsp; مضادة لنقص المناعة البشرية (HIV),<br />والمواد المعقدة (الأدوية التي لها القدرة على تقليل المعادن) وفيتامين (سي).&nbsp;<br />بالنسبة لبعض الأدوية، فقد يكون من الضروري أن تترك فترة زمنية أطول بين تناول أقراص فيلفورو&reg; وتناول الأدوية الإضافية (مثل<br />دوكسيسايكلين).<br />فمن غير المرجح أن يؤثر المنتج الطبي على قدرتك على القيادة أو على استخدام الأدوات والآلات.<br />الرجاء إخبار الطبيب أو الصيدلي إذا كنت</p><p dir="ltr"><br />,تعاني من اضطرابات أخرى ●<br />أو تعاني من الحساسية، أو ●<br />( تتناول منتجات طبية أخرى(حتى التي يتم شراؤها بدون وصفة طبية ●</p><p><br />ت. الحمل والإرضاع الطبيعي<br />الحمل<br />لا يجوز تناول دواء فيلفورو&reg;أثناء فترة الحمل إلا بعد استشارة طبيب.</p><p><br />الإرضاع الطبيعي<br />لا يجوز تناول دواء فيلفورو&reg;أثناء فترة الرضاعة إلا بعد استشارة طبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u>للبالغين</u><br />يقرر الطبيب الجرعة الموصي بها. إن الجرعة الأولية الموصي بها من أقراص فيلفورو &reg;هي 1,500 ملجم يوميًا (&nbsp;۳ أقراص). أثناء<br />علاج مستويات الفوسفات في مصل الدم، سيُعدل الطبيب الجرعة وفقًا لذلك. إن الحد الأقصى من الجرعة اليومية الموصي بها هو&nbsp; 3,000 ملجم (&nbsp;6 أقراص) يوميًا<br />يجب أن يتم تناول أقراص فيلفورو&reg;عن طريق الفم مع الوجبات.&nbsp;</p><p dir="ltr"><br />.يجب أن يتم مضغ الأقراص ويجب عدم ابتلاعها كاملة ●<br />.يمكن ان يتم طحن الأقراص ليسهل مضغها ●<br />.يجب عدم شرب أي سوائل إضافية تتجاوز مقدار السوائل المطلوبة لاضطراب الكلى ●<br />.يجب أن يتم تقسيم عدد الأقراص التي يتم تناولها يوميًا بين وجبات اليوم ●</p><p dir="ltr"><br />إذا تناولت العديد من الأقراص من غير القصد، فلا تتناول مزيدًا من الأقراص <strong>اتصل بمقدم الرعاية الصحية الخاص بك أو اسعَ<br />للحصول على مساعدة طبية على الفور</strong> إذا نسيت أن تتناول جرعة، فتخطِ الجرعة الفائتة وتناول الجرعة التالية في الوقت المعتاد لها</p><p>مع وجبة. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة. لا توقف تناول المنتج الطبي إلا بعد أن تتحدث مع الطبيب أو الصيدلي.</p><p><br /><u>الأطفال والمراهقون</u><br />&nbsp; &nbsp;لم يتم إجراء فحص استخدام وسلامة أقراص فيلفورو&reg;</p><p>في الأطفال والمراهقين حتى سن 18 عامًا بعد.<br />لا تغير الجرعة الموصوفة بنفسك. إذا شعرت أن التأثير الطبي مرتفع جدًا أو منخفض جدًا، فالرجاء التحدث مع الطبيب او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كمعظم الأدوية، يمكن أن يُسبب فيلفورو&reg; آثارً ا جانبية معينة ولكنها لا تصيب كافة المرضى.</p><p><br />تمت ملاحظة التأثيرات الجانبية التالية في المرضى الذين يتناولون أقرا ص فيلفورو &reg;:<br />شائعة جدًا (تؤثر على أكثر من مريض واحد في كل 10 مرضى): الإسهال، تغير لون البراز (براز أسود).<br />شائعة (تؤثر على عدد يتراوح بين مريض واحد و 10 مرضى في كل 100 مريض: (غثيان، إمساك، قيء، اضطرابات هضمية، ألم<br />في البطن، الانتفاخ، تغير مؤقت في لون الأسنان، طعم غريب للمنتج .<br />غير شائعة (تؤثر على عدد يتراوح بين مريض واحد و 10 مرضى في كل 1000 مريض: انتفاخ البطن (انتفاخ)، التهاب المعدة&nbsp; (التهاب بطانة التجويف البطني المخاطي)&nbsp;انزعاج في البطن، البلع بصعوبة، مرض ارتجاع معدي مريئي (GORD)&nbsp;تغير مؤقت في لون اللسان، مستويات مرتفعة أو منخفضة للكالسيوم في الدم، التعب، الحكة، الطفح الجلدي، الصداع، ضيق التنفس .<br />الإسهال يحدث مبكرًا في مرحلة العلاج ويخف مع مرور الوقت. يحدث دائمًا مع مستحضرات الحديد، يمكن أن يعاني المرضى الذين<br />يستخدمون فيلفورو في كثير من الأحيان من تغير لون البراز (براز أسود). قد لا يظهر وجود نزيف محتمل من الجهاز الهضمي (المعدة<br />والأمعاء) بسبب تغير لون البراز.</p><p><br />إذا كنت تعاني من أعراض إضافية، مثل تفاقم الشعور بالإعياء وضيق النفس، يُرجى الاتصال بالطبيب في الحال.</p><p><br />إذا اتضح أي من التأثيرات الجانبية أكثر خطورة، أو إذا لاحظت أي أعراض جانبية غير مدرجة في هذه النشرة، يُرجى إبلاغ طبيبك أو<br />الصيدلاني الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>- احتفظ بدواء فيلفورو&reg;بعيدًا عن مرأى ومتناول الأطفال.</strong><br />- يُرجى التخزين في العبوة الأصلية في درجات حرارة ليست أعلى من 30 &deg;درجة سيليزية .<br />-يجب أن يتم استخدام هذا المنتج الطبي حتى الوقت المحدد فقط كما هو مبين في &quot;تاريخ انتهاء الصلاحية&quot; الموجود على العبوة.<br />-يُرجى المحافظة دائمًا على غلق الزجاجة البلاستيكية بإحكام للحماية من الرطوبة.<br />-مدة الصلاحية بعد فتح الزجاجة البلاستيكية لأول مرة: 90 يومًا.ويحفظ بعيدًا عن متناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إن المادة الفعالة هي الحديد على هيئة أوكسي هيدروكسيد سكروز الحديد الثلاثي (خليط من أوكسي هيدروكسيد الحديد متعدد النوى<br />(الثلاثي) والسكروز والنشا).<br />يحتوي كل قرص على 500 ملجم من الحديد على هيئة&nbsp;أوكسي هيدروكسيد سكروز الحديد الثلاثي (خليط من أوكسي هيدروكسيد الحديد<br />متعدد النوى (الثلاثي) والسكروز والنشا) والمنكهات والسواغات.</p><p><br />السواغات<br />ستيارات المغنيسيوم، سيليكا (غروانية لا مائية)، نكهة التوت، نيو هيسبيريدين ثنائي هايدرو كالكون .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><br />الأقراص القابلة للمضغ مستديرة وبنية اللون قابلة للشطر وموسومة برمز PA500 على جانب واحد.&nbsp;<br />تعبّأ الأقراص في زجاجات بلاستيكية تحتوي على <strong>90</strong> قرصًا قابلاً للمضغ.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;صاحب ترخيص التسويق والمصدر:<br />.Vifor (international) Inc<br />Rechenstrasse 37, 9014 St. Gallen<br />Switzerland</p><p><br />&nbsp;موقع التصنيع و التعبئة<br />Corden Pharma Fribourg SA<br />Route de Moncor 10, 1752 Villars-sur-Gl&acirc;ne</p><p>Switzerland</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ مراجعة النشرة: مايو 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VELPHORO® 500mg Chewable tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Polynuclear iron(III) oxyhydroxide in a mixture with sucrose and starch.
One Velphoro tablet contains 500 mg of iron as iron(III) oxyhydroxide.

Excipients
Magnesium stearate
Silica (colloidalis anhydrica)
woodberry flavour
Neohesperidine dihydrochalcone.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablets.
They are round, brown, biplanar tablets, debossed with PA500 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hyperphosphataemia in adult patients with chronic renal insufficiency under dialysis<br />treatment (haemodialysis, peritoneal dialysis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets must be taken orally with food and chewed. Do not swallow them whole.</p><p><br />Use<br />Velphoro is a chewable tablet that must be taken with meals. In order to increase phosphate<br />absorption from food, the daily dose should be divided between the meals of the day.<br />Patients do not need to drink more fluids than usual. The tablets must be chewed and must<br />not be swallowed whole. The tablets can be broken into small pieces. If you forget to take<br />one or more doses, the normal dose must be taken as usual with the next meal.</p><p><strong>Initial dose</strong><br />The recommended initial dose of Velphoro is 3 tablets (1,500 mg) per day.</p><p><br /><strong>Titration and maintenance</strong><br />Serum phosphate levels must be monitored and the Velphoro dose increased or decreased<br />every 2&ndash;4 weeks in 500 mg increments (1 tablet) per day until an acceptable serum<br />phosphate level is attained. After that, the serum phosphate levels must be monitored<br />regularly.<br />In clinical practice, treatment takes place based on the need to check the serum phosphate<br />levels. Patients who respond to Velphoro usually reach the optimal serum phosphate level<br />using a daily dose of 1,500 to 2,000 mg (3&ndash;4 tablets).</p><p><br /><strong>Maximum daily dose</strong><br />The maximum daily dose is 3,000 mg (6 tablets) per day.</p><p><br /><strong>Specific dosage instructions<br />Paediatric population</strong><br />The efficacy and safety of Velphoro in children and adolescents under 18 years old has not<br />been studied.</p><p><br /><strong>Elderly patients</strong><br />In clinical studies, Velphoro was administered to 248 patients aged &ge; 65. 73 of the patients<br />were &ge;75 years old. No special posology or administration guidelines for elderly patients were<br />used in the study.</p><p><br /><strong>Patients with hepatic diseases</strong><br />There are only limited clinical data on the use of Velphoro in patients with hepatic diseases.<br />Patients with elevated transaminases (&ge;3&times; ULN) were not investigated in the clinical study.<br />Velphoro should be administered with care in these patients (see &ldquo;Special warnings and<br />precautions for use&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients (see “Composition”)
- Congenital or acquired iron overload conditions (such as haemochromatosis)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Long-term experience with Velphoro is limited. In the pivotal clinical studies, the maximum<br />observation time was 55 weeks. It is recommended that the iron homeostasis be checked at<br />regular intervals in the case of long-term use.<br />There are only limited data on the use of Velphoro in patients with peritoneal dialysis (see<br />&ldquo;Properties/Effects&rdquo;).<br />Patients with a history of peritonitis, patients with clinically relevant diseases of the liver or<br />gastrointestinal tract or those who had had major gastrointestinal operations were not<br />investigated in clinical studies.<br />Velphoro should only be administered with caution in the aforementioned patient groups and<br />with strict monitoring of clinical status, serum electrolytes and iron homeostasis.<br />Velphoro can lead to a (reversible) discolouration of the teeth and tongue. There is often a<br />darkening of the stool in patients taking Velphoro. Velphoro does not affect the common<br />systems to test for occult blood in the stool.<br />Velphoro contains sucrose. Patients with a rare hereditary fructose intolerance, glucosegalactose<br />malabsorption or saccharase-isomaltase deficiency should not take this medicinal<br />product. It may be harmful to the teeth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with dialysis patients.<br />Interaction studies have only been performed with healthy subjects.<br />Losartan, furosemide, digoxin, warfarin and omeprazole were studied in clinical studies on<br />interactions with other medicinal products. Concomitant administration of Velphoro did not<br />affect the bioavailability of these medicinal products. In in vitro studies, the adsorption of the<br />following medicinal products to Velphoro was observed: alendronate, doxycycline,<br />levothyroxine, atorvastatin, doxercalciferol and paricalcitol. These interactions can lead to a<br />decreased bioavailability of the medicinal products mentioned, which, apart from<br />doxercalciferol and paricalcitol, have not been studied in clinical trials. This means that<br />clinically relevant interactions cannot be ruled out.. Therefore, these medicinal products<br />should be administered at least 1 hour before or 2 hours after Velphoro. In addition, clinical<br />studies demonstrated no impact of Velphoro on iPTH lowering effect of oral Vitamin D<br />analogues(e.g. doxercalciferol, paricalcitol).<br />Medicinal products that are known to interact with iron (e.g. bisphosphonates, tetracycline,<br />levothyroxine, ciprofloxacin, mycophenolate, mycophenolate mofetil, integrase inhibitors and<br />complexing agents in general) should be administered at least 1 hour before or 2 hours after<br />Velphoro. For some medicinal products, it may be necessary to leave a longer period of time between taking Velphoro and taking the additional medicinal product (e.g. doxycycline). The Summary of Product Characteristics for the additional medicinal product should also be<br />consulted.<br />The effect of vitamin C on the resorption of iron from Velphoro has not been investigated.<br />Vitamin C should therefore generally be administered at least 1 hour before or 2 hours after<br />Velphoro.<br /><em>In vitro</em> studies with the following medicinal products revealed no significant interactions:<br />acetylsalicylic acid, cephalexin, cinacalcet, ciprofloxacin, clopidogrel, enalapril,<br />hydrochlorothiazide, metformin, metoprolol, nifedipine, pioglitazone, simvastatin and<br />quinidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no clinical data on the use of Velphoro during pregnancy.<br />Animal studies on reproductive and developmental toxicity have not demonstrated any<br />undesirable effects with respect to pregnancy, embryonic and foetal development, the birth<br />process or postnatal development.<br />Use with caution during pregnancy.</p><p><br /><strong>Breastfeeding</strong><br />There are no clinical data on the use of Velphoro in breastfeeding mothers. The insignificant<br />absorption of iron from Velphoro makes excretion into breast milk unlikely. In order to decide<br />whether to continue breastfeeding or to continue the Velphoro therapy, the benefits for the<br />breastfed infant and the benefits of the Velphoro therapy for the mother must be weighed<br />against each other.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no studies on the effects of taking Velphoro on the ability to drive and use<br />machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been reported in clinical studies with Velphoro.<br />Frequency of undesirable effects:<br />Very common: &ge;1/10<br />Common: &ge;1/100, &lt;1/10<br />Uncommon: &ge;1/1000, &lt;1/100<br />Rare: &ge;1/10,000, &lt;1/1000<br />Velphoro was studied in two active substance-controlled pivotal studies. A total of n=778<br />haemodialysis patients and n=57 peritoneal dialysis patients were treated for up to a<br />maximum of 55 weeks. The dosage for these patients was between 250 mg iron/day and<br />3,000 mg iron/day.</p><p><br />Metabolism and nutrition disorders<br />Uncommon: hypercalcaemia, hypocalcaemia</p><p><br />Nervous system disorders<br />Uncommon: headache</p><p><br />Respiratory, thoracic and mediastinal disorders<br />Uncommon: dyspnoea</p><p><br />Gastrointestinal disorders<br />Very common: diarrhoea*, faeces discoloured<br />Common: nausea, constipation, vomiting, dyspepsia, abdominal pain, flatulence,<br />discolouration of the teeth<br />Uncommon: abdominal distension (tightness in the abdomen), gastritis, abdominal discomfort,<br />dysphagia, gastro-oesophageal reflux disease (GORD), discolouration of the tongue, loss of<br />appetite</p><p><br />Skin and subcutaneous tissue disorders<br />Uncommon: pruritus, rash</p><p><br />General disorders and administration site conditions<br />Common: abnormal product taste<br />Uncommon: fatigue</p><p>Description of selected undesirable effects<br />*Diarrhoea11.6% of clinical study participants suffered from diarrhoea. In long-term studies of<br />over 55 weeks, the majority of diarrhoeal instances were minor (59.8%) and transient, and<br />occurred soon after the initiation of treatment. It caused 3.1% of the patients to discontinue<br />treatment.</p><p><br />To reports any side effect(s):<br />Saudi Arabia:</p><p style="text-align:center"><br /><strong>To report any side effect(s):</strong></p><p><br />-The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No instances of overdose with Velphoro are known. An overdose should be treated in<br />accordance with the common clinical practice.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of action</strong><br />The active substance of Velphoro is a mixture of polynuclear iron(III) oxyhydroxide<br />(pn-FeOOH), sucrose and starch. In the aqueous environment of the GI tract, phosphate<br />binding occurs through ligand exchange between hydroxyl groups and/or water and<br />phosphate ions through the physiological pH value of the GI tract.<br />Both serum phosphate levels and calcium phosphate products decrease due to reduced<br />phosphate absorption from food.</p><p><strong>Clinical efficacy and safety</strong><br />N=835 patients have been treated with Velphoro in clinical studies at a dosage of up to<br />3,000 mg iron/day.<br />Velphoro was studied in two pivotal studies: in a 6week,<br />open-label, randomised, activecontrolled (sevelamer hydrochloride), parallel-group, dose-finding study; and a 55week,<br />open-label, randomised, active-controlled (sevelamer carbonate) safety and efficacy study.</p><p><br /><strong>A 6week open-label randomised, active-controlled, dose-finding study with<br />haemodialysis patients suffering from hyperphosphataemia</strong><br />A 6week randomised, open-label, active-controlled phase II dose-finding study was<br />conducted with 154 haemodialysis patients. Of these, 128 patients received Velphoro in a<br />fixed dose and 26 patients received a comparator product (sevelamer hydrochloride).<br />Velphoro showed a significant reduction in the serum phosphate level compared to the<br />baseline at doses of 1,000 mg iron/day to 2,500 mg iron/day. Overall, the reduction of the<br />serum phosphate in this dose range seemed to be comparable to that for treatment with<br />sevelamer hydrochloride (4,800 mg/day).</p><p><br /><strong>27week,open-label, randomised, active-controlled safety and efficacy study<br />(PACL05A)followed by a prolonged 28week extended safety study (PACL05B)<br />of dialysis patients with hyperphosphataemia</strong><br />In study PACL05A, 1,055 patients (968 haemodialysis and 87 peritoneal dialysis) with<br />hyperphosphataemia were investigated. They received Velphoro (initial dose 1,000 mg<br />iron/day, 707 patients) or the comparator product sevelamer carbonate (initial dose 2.4 g,<br />348 patients).<br />Dose titration was possible for a period of 8 weeks at 2week intervals for efficacy and safety<br />reasons. The daily dose was able to be increased by 500 mg iron (Velphoro) and 2.4 g<br />(sevelamer) each time. The target phosphate range was defined as 0.81&ndash;1.78 mmol/L (2.5&ndash;<br />5.5 mg%). In the case of values outside of this target range or problems with tolerability, the<br />dose was adjusted. After week 8, the dose was kept constant until week 12. It was also<br />possible to reduce the dose during this period for reasons of tolerability.<br />From week 12, titrations for efficacy and safety reasons were possible again. The dose was<br />adjusted every four weeks.<br />After 24 weeks, 94 haemodialysis patients who were treated with Velphoro were randomised<br />again and received Velphoro for an additional 3 weeks either at its maintenance dose<br />(45 patients) or at a non-effective low dose (250 mg iron/day, 49 patients). At the end of this<br />3week period (week 27), a primary efficacy analysis was performed with regard to the<br />change in serum phosphorus compared to week 24. The Velphoro maintenance dose (1,000&nbsp;to 3,000 mg iron/day) was shown to be significantly superior to the Velphoro control dose (250 mg iron/day) in terms of maintaining the phosphate-reducing effect.<br />The maximum daily dose of Velphoro was 3,000 mg iron/day and the minimum daily dose<br />was 1,000 mg iron/day.<br />The study also met the predefined secondary endpoint, which was to demonstrate the noninferiority<br />of Velphoro compared to the active comparator product (sevelamer carbonate)<br />after 12 weeks of treatment. The average change in the serum phosphate at week 12<br />compared to the baseline was 0.71 mmol/L in the Velphoro group and 0.79 mmol/L in the<br />sevelamer group.<br />After concluding PACL05A, 658 patients (597 haemodialysis and 61 peritoneal dialysis<br />patients) continued treatment in the original randomisation with either Velphoro (n=391) or<br />sevelamer carbonate (n=267) in the context of the 28week safety extension study(PACL05B).</p><p><br />The efficacy of Velphoro in terms of lowering serum phosphate levels was maintained during<br />the entire observation period. The average number of tablets to be taken in this part of the<br />study was around 4 tablets per day for the patients treated with Velphoro compared to<br />around 10 tablets per day for those on sevelamer.<br /><em>Post-authorisation data</em></p><p><br />A prospective, non-interventional, post-authorisation safety study (VERIFIE) has been<br />conducted, evaluating the short- and long-term (up to 36 months) safety and effectiveness of<br />Velphoro in adult patients on haemodialysis (N=1,198) or peritoneal dialysis (N=160), who<br />were followed in routine clinical practice for 12 to 36 months (safety analysis set, N=1,365).<br />During the study, 45% (N=618) of these patients were concomitantly treated with phosphate<br />binder(s) other than Velphoro.</p><p><br />In the safety analysis set, the most common undesirable effects were diarrhoea and<br />discoloured faeces, reported by 14% (N=194) and 9% (N=128) of patients, respectively. The<br />incidence of diarrhoea was highest in the first week and decreased with duration of use.<br />Diarrhoea was of mild to moderate intensity in most patients and resolved in the majority of<br />patients within 2 weeks. Discoloured (black) faeces is expected for an oral iron-based<br />compound, and may visually mask gastrointestinal bleeding. For 4 of the 40 documented<br />concomitant gastrointestinal bleeding events, Velphoro-related stool discolouration was<br />reported as causing an insignificant delay in diagnosis of gastrointestinal bleeding, without<br />affecting patient health. In the remaining cases, no delay in diagnosis of gastrointestinal<br />bleeding has been reported.</p><p>The results from this study showed that the effectiveness of Velphoro in a real-life setting<br />(including concomitant use of other phosphate binders in 45% of patients), was in line with<br />that observed in the phase 3 clinical study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Velphoro works by binding phosphate in the GI tract, so systemic availability is not relevant to<br />the efficacy.</p><p><br /><strong>Absorption</strong><br />The active substance of Velphoro, pnFeOOH is practically insoluble and is therefore not<br />absorbed. Its degradation products, mononuclear iron species, can, however, be released<br />from the surface of pnFeOOH and absorbed.<br />The iron absorption from Velphoro&rsquo;s radioactively labelled active substance, 2,000 mg iron a<br />day, was examined in 16 patients with chronic kidney disease (8 predialysis and<br />8 haemodialysis patients) and in 8 healthy subjects with low iron reserves (serum ferritin<br />&lt;100 mcg/L). In healthy subjects, the median uptake of radioactively labelled iron in the blood<br />on day 21 was 0.43% of the dose (min. 0.16% &ndash; max. 1.25%). In pre-dialysis patients, the<br />median uptake of radioactively labelled iron in the blood on day 21 was 0.06% of the dose<br />(corresponding to a median uptake of 1.2 mg of iron (minimum value 0.16 mg &ndash; maximum<br />value 8.8 mg of iron)). In haemodialysis patients, the median uptake was 0.02% of the dose<br />(corresponding to a median uptake of 0.4 mg of iron (minimum value 0 mg iron&ndash; maximum<br />value 0.8 mg of iron)). Blood concentrations of radioactively labelled iron were very low and<br />restricted to the erythrocytes.</p><p><br /><strong>Distribution</strong><br />Due to the low solubility and the decomposition characteristics of Velphoro, no classical<br />pharmacokinetic studies have been carried out and the distribution of the medicinal product<br />has not been determined.</p><p><br /><strong>Biotransformation</strong><br />The active substance of Velphoro, pnFeOOH, is not metabolised. The degradation products<br />of Velphoro, mononuclear iron species, can be absorbed, however. It can be assumed that<br />this iron goes into the physiological iron metabolism.<br />In vitro data suggest that the sucrose and starch components of the active medicinal<br />substance may be digested to form glucose and fructose or maltose and glucose. These<br />compounds can be absorbed into the blood.</p><p><strong>Elimination</strong><br />In animal studies with rats and dogs where the 59Fe Velphoro medicinal active substance was<br />administered orally, radioactively labelled iron was detected in faeces but not in urine.<br />On the basis of these preclinical studies, the excretion of the iron that is not absorbed (&gt;99%<br />of the dose administered) is expected in the faeces.</p><p><br /><strong>Kinetics in special patient groups</strong><br />No studies have been carried out in children or patients with reduced hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of<br />safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction and development.<br />Carcinogenicity studies were conducted in mice and rats.<br />A carcinogenic effect in mice was not clearly demonstrated. After two years of treatment,<br />membrane hyperplasia with the formation of diverticula/cysts was observed in the colon and<br />appendix of mice; however, this was regarded as a species-specific effect, as no<br />diverticula/cysts occurred in long-term studies with rats or dogs. In the case of rats, there was<br />a slightly increased incidence of benign Ccell adenoma in the thyroid glands of males who<br />had received sucroferric oxyhydroxide in the highest dose. The view is that this is most likely<br />an adaptive reaction to the pharmacological effect of the medicinal product.</p><p><br />Fertility<br />There are no data indicating the effects of Velphoro on human fertility. In animal studies, no<br />negative effects were observed on mating performance, fertility or litter parameters after<br />treatment with Velphoro.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Magnesium stearate<br />Silica (colloidalis anhydrica)</p><p>woodberry flavour<br />Neohesperidine dihydrochalcone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Velphoro must only be used up to the designated date as indicated with “EXP” on the
package.
Shelf life after first opening the plastic bottle: 90 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package at temperatures not above 30&deg;C.<br />Always keep the plastic bottle tightly closed in order to protect its contents from moisture.<br />Keep out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles containing 90 chewable tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Please refer to section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vifor (International) Inc.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>